Blog

Medicines360 Welcomes Margot Fahnestock as Vice President of Strategic Development

September 25, 2019

Medicines360 is delighted to announce that Margot Fahnestock has joined our team as Vice President of Strategic Development. Margot will be responsible for planning, organizing, and implementing all of our high-impact strategic programming and fundraising efforts both in the U.S. and globally.

Margot Fahnestock

Before Medicines360, Margot served as a Program Officer in the William and Flora Hewlett Foundation’s Global Development and Population Program. At Hewlett, Margot was responsible for making grants to reduce unintended pregnancies and improve reproductive health and rights in Africa. Margot was also a founding member and catalyst for the Ouagadougou Partnership, which has mobilized more than $200 million in additional funding for family planning in Francophone West Africa since 2012. She also led an effort with the Hewlett Foundation, Bill and Melinda Gates Foundation, and Children’s Investment Fund Foundation to use human-centered design to strengthen adolescent reproductive health services.

Prior to Hewlett, Margot managed West Africa field operations for a USAID-funded health policy initiative at the Futures Group (now Palladium), for which she provided technical and managerial oversight for family planning, HIV/AIDS, and malaria policy programs. After graduating from the University of California, Los Angeles with a bachelor’s degree in English literature, Margot spent two years as a U.S. Peace Corps volunteer teaching English in a rural town in Mali. Margot also has a master’s degree in public policy from the University of Chicago.

Please join us in welcoming Margot to the team!

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

Share This

©2022 Medicines360. A 501(c)(3) tax-exempt organization. Medicines360® and its design are registered trademarks of Medicines360.

Avibela® is a registered trademark of Medicines360 in countries across Africa, South and Southeast Asia, Central America, and the Caribbean.

Impact RH360® is a registered trademark of Medicines360 in Madagascar, Rwanda, Uganda, South Africa, and Zambia.

All other trademarks are property of their respective owners.

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.